Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria
Study Details
Study Description
Brief Summary
This is an open label dose adjusted phase II trial of the oral farnesyltransferase inhibitor (FTI) lonafarnib (SCH66336) for patients with HGPS and progeroid laminopathies.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare "premature aging" disease in which all children die at an average age of thirteen years (range 8-20 years) of severe atherosclerosis leading to strokes and heart attacks. It is a multisystem disease with objective clinical markers for disease progression. These include abnormalities in growth and body composition, bone mineral density, joint function, endocrine function, alopecia, and vascular disease. There is no effective therapy for any of the progressive and deleterious aspects of this disorder.
The gene defect causing HGPS and most progeroid laminopathies has been identified as a mutation in the gene LMNA, coding for the nuclear protein lamin A. Lamin A is normally expressed by most differentiated cells, and requires posttranslational farnesylation to incorporate into the nuclear membrane. The lamin A C-terminal peptide, including the farnesyl group, is subsequently cleaved, and mature lamin A becomes a prominent component of the nuclear scaffold just internal to the nuclear membrane, affecting nuclear structure and function.
In most cases, HGPS is a sporadic autosomal dominant disease caused by a single base alteration (henceforth designated as G608G) in the LMNA gene, which creates a cryptic splice site giving rise to an altered lamin A protein product in which 50 amino acids are deleted. The defective protein product in HGPS (henceforth progerin) lacks the cleavage site for removal of the C-terminal farnesylated peptide, and likely produces disease via dominant negative effects on the nuclear structure and function of various cell types that express lamin A. Most other progeroid laminopathies are caused by various mutations in the LMNA gene, which also subsequently creates abnormally functioning lamin A.
Lonafarnib is a farnesyltransferase inhibitor that blocks the post-translational farnesylation of prelamin A and other proteins that are targets for farnesylation. Farnesylation is essential for the function of both mutant and non-mutant lamin A proteins, including progerin. Therefore, farnesyltransferase inhibitors are ideal candidates for treatment of HGPS, which is caused by a protein (progerin) that likely depends on carrying a farnesyl group to execute its aberrant functions.
Both cell culture and mouse model studies of HGPS demonstrate improved phenotype after exposure to FTI. In vitro, exposure of HGPS skin fibroblasts and progerin-transfected HeLa cells to FTIs, including lonafarnib, prevents preprogerin from intercalating into the nuclear membrane where it normally functions, and eliminates nuclear deformity. In vivo, three Progeria-like mouse models show no appreciable signs of toxicity after FTI administration. In all three of these models, disease is significantly reduced when compared to age-matched controls after oral administration of FTI.
We propose that clinical features of HGPS can be ameliorated or reversed by blocking posttranslational farnesylation via treating patients with lonafarnib. We hypothesize that reduction of the quantity of functional progerin or, in the case of other progeroid laminopathies, other abnormal lamin proteins, will improve disease signs, symptoms and outcome. We also hypothesize that the toxicity profile of FTI inhibition using lonafarnib will be similar to that observed in children with malignant brain tumors treated with the compound.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Lonafarnib All subjects initiated oral Lonafarnib twice daily at a dose of 115mg/m2 and escalated to 150 mg/m2. Two subjects de-escalated to 115mg/m2 following toxicity. |
Drug: Lonafarnib
Lonafarnib will be taken orally, twice per day, by all patients enrolled on this study. The drug is supplied to patients in capsule form, and for patients who are unable to swallow pills, the drug may be dissolved into solution. Every patient will start lonafarnib therapy at a dose of 115mg/kg. The study allows for patients to receive a dose escalation (up to 150mg/kg) if the drug is being well-tolerated. Every patient enrolled on this study will undergo two years of lonafarnib therapy.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Proportion of Participants With Successful Rate of Weight Gain [Assessed at weeks 16, 32, 52, 68, 84 and 104]
Activity was assessed by determining the change in rate of weight gain over two years from baseline (determined pre-therapy for each patient). Primary outcome success was predefined as a 50% increase over pre-therapy in estimated annual rate of weight gain, or change from pre-therapy weight loss to statistically significant on-study weight gain.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
All patients must have confirmatory mutational analysis showing G608G mutation in the lamin A gene.
-
Patients with progeroid laminopathies, showing clinical signs of Progeria but with other confirmed mutations in LMNA will be eligible for therapy. This population will be analyzed separately from those with the classical mutations.
-
Patients must be willing and able to come to Boston for appropriate studies and examinations approximately once every 4 months.
-
Patients must have a minimum of one year of weight data available, with five data points or more, each separated by one month or more over a one year period and approval by the study team.
-
APC (ANC + bands + monocytes = APC) > 1,000/ml, Platelets > 75,000/ml (transfusion independent); Hemoglobin >9g/dl.
-
creatinine less than or equal to 1.5 times normal for age or GFR > 70 ml/min/1.73m2.
-
bilirubin less than or equal to 1.5 x upper limit of normal for age; SGPT (ALT) < and SGOT (AST) < 5 x normal range for age.
-
PT/PTT < 120% upper limit of normal OR PI approval.
-
No overt renal, hepatic, pulmonary disease or immune dysfunction.
-
Patients taking growth hormone when entering the study must have pretreatment weight measures while on growth hormone which are specified above. In addition, patients must remain on growth hormone treatment for the duration of the present clinical trial. Patients entering the trial not on growth hormone must remain off of growth hormone for the duration of their participation.
-
Signed informed consent according to institutional guidelines must be obtained and patient must begin therapy within twenty eight (28) days.
Exclusion Criteria:
-
Patient must not be receiving any other experimental drug therapy.
-
Patients must not be taking medications that significantly affect the metabolism of lonafarnib.
-
Subjects who have known or suspected hypersensitivity to any of the excipients included in the formulation should not be treated.
-
Patients must not be pregnant or breast-feeding. Female patients of childbearing potential must have negative serum or urine pregnancy test. Male and female patients of reproductive potential must agree to use a medically accepted form of birth control while on study and up to 10 weeks after treatment. It is permissible for female patients to take oral contraceptives or other hormonal methods while receiving treatment with lonafarnib.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Children's Hospital Boston | Boston | Massachusetts | United States | 02115 |
Sponsors and Collaborators
- Monica E. Kleinman
- Schering-Plough
Investigators
- Study Chair: Mark W Kieran, MD, PhD, Dana-Farber Cancer Institute, Children's Hospital Boston
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 07-01-007
- P05009
- NCT00426088
Study Results
Participant Flow
| Recruitment Details | 26 patients with classic HGPS from 16 countries were enrolled from May through October 2007 at Boston Children's Hospital. 2 additional patients had nonclassic mutations and are not included in the analyses. |
|---|---|
| Pre-assignment Detail | One additional patient signed consent but withdrew from the protocol before receiving therapy. |
| Arm/Group Title | Lonafarnib |
|---|---|
| Arm/Group Description | Lonafarnib (Merck & Co., Inc.) dosing was initiated at 115 mg/m2 and was increased to 150 mg/m2 after an adjustment period of at least 4 mo. Dosage was reduced back to 115 mg/m2 for patients experiencing drug-related grade 3 or 4 toxicity and also not responding to supportive care. Once dosage was reduced, patients were permitted to increase the dose of lonafarnib. Patients received oral lonafarnib either by capsule or liquid suspension dispersed in Ora-Blend SF or Ora-Plus (Paddock Laboratories, Inc.) every 12 ± 2 h for a period of 24-29 mo. |
| Period Title: Overall Study | |
| STARTED | 29 |
| Received Treatment | 28 |
| COMPLETED | 27 |
| NOT COMPLETED | 2 |
Baseline Characteristics
| Arm/Group Title | Lonafarnib |
|---|---|
| Arm/Group Description | Lonafarnib (Merck & Co., Inc.) dosing was initiated at 115 mg/m2 and was increased to 150 mg/m2 after an adjustment period of at least 4 mo. Dosage was reduced back to 115 mg/m2 fo patients experiencing drug-related grade 3 or 4 toxicity and also not responding to supportive care. Once dosage was reduced, patients were permitted to increase the dose of lonafarnib. Patients received oral lonafarnib either by capsule or liquid suspension dispersed in Ora-Blend SF or Ora-Plus (Paddock Laboratories, Inc.) every 12 ± 2 h for a period of 24-29 mo. |
| Overall Participants | 25 |
| Age (years) [Mean (Standard Deviation) ] | |
| Mean (Standard Deviation) [years] |
7.0
(3)
|
| Sex: Female, Male (Count of Participants) | |
| Female |
14
56%
|
| Male |
11
44%
|
Outcome Measures
| Title | Proportion of Participants With Successful Rate of Weight Gain |
|---|---|
| Description | Activity was assessed by determining the change in rate of weight gain over two years from baseline (determined pre-therapy for each patient). Primary outcome success was predefined as a 50% increase over pre-therapy in estimated annual rate of weight gain, or change from pre-therapy weight loss to statistically significant on-study weight gain. |
| Time Frame | Assessed at weeks 16, 32, 52, 68, 84 and 104 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Results are reported for the 25 patients with classic HGPS who completed at least 2y of therapy. One additional patient with a prior history of strokes died of a stroke after 5 mo on study and is not included in the analysis. Two additional patients had nonclassic mutations and are not included in this analysis. |
| Arm/Group Title | Lonafarnib |
|---|---|
| Arm/Group Description | Lonafarnib (Merck & Co., Inc.) dosing was initiated at 115 mg/m2 and was increased to 150 mg/m2 after an adjustment period of at least 4 mo. Dosage was reduced back to 115 mg/m2 for patients experiencing drug-related grade 3 or 4 toxicity and also not responding to supportive care. Once dosage was reduced, patients were permitted to increase the dose of lonafarnib. Patients received oral lonafarnib either by capsule or liquid suspension dispersed in Ora-Blend SF or Ora-Plus (Paddock Laboratories, Inc.) every 12 ± 2 h for a period of 24-29 mo. |
| Measure Participants | 25 |
| Number (95% Confidence Interval) [proportion of participants] |
0.36
1.4%
|
Adverse Events
| Time Frame | Up to 2 years: Assessed at a minimum at weeks 16, 32, 52, 68, 84 and 104 | |
|---|---|---|
| Adverse Event Reporting Description | ||
| Arm/Group Title | Lonafarnib | |
| Arm/Group Description | Lonafarnib (Merck & Co., Inc.) dosing was initiated at 115 mg/m2 and was increased to 150 mg/m2 after an adjustment period of at least 4 mo. Dosage was reduced back to 115 mg/m2 fo patients experiencing drug-related grade 3 or 4 toxicity and also not responding to supportive care. Once dosage was reduced, patients were permitted to increase the dose of lonafarnib. Patients received oral lonafarnib either by capsule or liquid suspension dispersed in Ora-Blend SF or Ora-Plus (Paddock Laboratories, Inc.) every 12 ± 2 h for a period of 24-29 mo. Patients were monitored for liver, kidney, and hematological toxicity each month for the first 3 mo by their local physicians and every 4 mo in Boston for the duration of the study. Adverse events were monitored and recorded throughout the study. | |
All Cause Mortality |
||
| Lonafarnib | ||
| Affected / at Risk (%) | # Events | |
| Total | / (NaN) | |
Serious Adverse Events |
||
| Lonafarnib | ||
| Affected / at Risk (%) | # Events | |
| Total | 10/28 (35.7%) | |
| Blood and lymphatic system disorders | ||
| Hypokalemia | 1/28 (3.6%) | 1 |
| Gastrointestinal disorders | ||
| Vomiting | 2/28 (7.1%) | 2 |
| Infections and infestations | ||
| Bacterial infection | 1/28 (3.6%) | 1 |
| Musculoskeletal and connective tissue disorders | ||
| Extremity-lower (gait/walking) | 1/28 (3.6%) | 1 |
| Nervous system disorders | ||
| Stroke | 3/28 (10.7%) | 3 |
| Subdural hematoma | 1/28 (3.6%) | 1 |
| Neuropathy: Sensory | 1/28 (3.6%) | 1 |
Other (Not Including Serious) Adverse Events |
||
| Lonafarnib | ||
| Affected / at Risk (%) | # Events | |
| Total | 0/28 (0%) | |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Dr. Mark Kieran |
|---|---|
| Organization | Dana-Farber Cancer Institute |
| Phone | 617-632-4907 |
| mark_kieran@dfci.harvard.edu |
- 07-01-007
- P05009
- NCT00426088